Biosense Webster Successfully Completes First Clinical Atrial Fibrillation Ablation Cases in the European Union Using the THERMOCOOL(R) SMARTTOUCH(TM) Contact Force Sensing Catheter
– THERMOCOOL(R) SMARTTOUCH(TM) Catheter from Biosense Webster Enables
Contact Force Sensing in the Ablation of Atrial Fibrillation
Biosense Webster, Inc., a Johnson & Johnson company, and a worldwide
leader in the diagnosis and treatment of cardiac arrhythmias, announced the
successful completion of the first clinical cases with the new THERMOCOOL(R)
SMARTTOUCH(TM) Contact Force Sensing Catheter in the European Union,
following recent CE-marking of the product.
The THERMOCOOL(R) SMARTTOUCH(TM) Catheter is the most advanced catheter
developed by Biosense Webster to date. During cardiac ablation, the
THERMOCOOL(R) SMARTTOUCH(TM) Catheter enables the measurement of catheter tip
contact force and direction inside the heart. The force and contact
information is graphically displayed on the CARTO(R) 3 Mapping and Navigation
System with the CARTO(R) 3 SMARTTOUCH(TM) Software Module thus creating the
only fully integrated solution in the electrophysiology market which combines
contact force, 3D mapping and navigation capabilities.
performed the first human cases with the THERMOCOOL(R) SMARTTOUCH(TM)
Catheter and CARTO(R) 3 System and says: “This is a breakthrough technology.
The additional force reading parameter gives me the confidence that it
improves my ablation procedure to better serve my patients’ symptoms and
quality of life.”
The THERMOCOOL(R) SMARTTOUCH(TM) Catheter combines Biosense Webster’s
market-leading irrigated ablation technology and the accurate visualization,
for which the CARTO(R) 3 System is renowned globally, with innovative
force-sensing capabilities. By displaying precise contact force and direction
information, the THERMOCOOL(R) SMARTTOUCH(TM) Catheter provides an important
new parameter for the mapping and ablation of complex cardiac arrhythmias,
such as Atrial Fibrillation (AF).
“THERMOCOOL(R) SMARTTOUCH(TM) Catheter brings important new force reading
information to physicians when performing cardiac ablation, and will provide
them with a new and important measure that can help further improve
procedural outcomes. This breakthrough technology continues our commitment to
bringing advanced tools to the Cardiac Electrophysiology community, so that
they may better serve their patients,” said
President, Biosense Webster, Inc.
About Atrial Fibrillation and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading
cause of stroke among people 65 years and older. Worldwide, it is estimated
that 20 million people have Atrial Fibrillation, yet only 100,000 are treated
with ablation every year. The public health implications of Atrial
Fibrillation are a growing concern because those with Atrial Fibrillation are
at an increased risk of morbidity and mortality as well as a reduced quality
Most patients with Atrial Fibrillation today are treated with
anti-arrhythmic drugs (AADs), even though about half of them are refractory
to these drugs. During cardiac ablation, energy is delivered through the
catheter to those areas of the heart muscle causing the abnormal heart
rhythm. This energy “disconnects” the pathway of the abnormal rhythm. Cardiac
ablation is the standard of care for “simple” arrhythmias, like
Wolff-Parkison-White Syndrome and atrioventricular nodal re-entry tachycardia
(AVNRT), and is increasingly being used for more complex arrhythmias like
ventricular tachycardia and Atrial Fibrillation.
company’s scientific advisory board and provides other consulting services.
About Biosense Webster, Inc.
Biosense Webster, Inc., a Johnson & Johnson company, pioneered
electrophysiology diagnostic catheters more than 30 years ago and continues
to lead the industry as an innovative provider of advanced diagnostic,
therapeutic and mapping tools. As the leader in navigation systems and
ablation therapy, Biosense Webster, Inc.’s technology includes the largest
installed base of navigation systems worldwide in leading hospitals and
teaching institutions. With its proprietary products the company is changing
the way electrophysiologists diagnose and treat arrhythmias. Biosense
Webster, a Division of Johnson & Johnson Medical SA, Waterloo,
the European authorized representative of Biosense Webster, Inc.
Contact: Name: Ulrike Domany Director Public Affairs & Communication EMEA (m) +43-664-83-504-83 Name: Chris Steel APCO Worldwide (m) +44-7920-837095
SOURCE Biosense Webster, Inc.